Global Diabetes Devices Market Size, Share & Trends Analysis Report By Type (Blood Glucose Monitoring Devices, Insulin Delivery Devices, Continuous Glucose Monitoring Devices, Self-Monitoring Blood Glucose (SMBG) Systems), By Technique (Invasive, Non-Invasive), By Type (Wearable, Non-Wearable), By Distribution Channel, By End-use (Hospitals, Homecare, Institutional Sales, Retail Sales, Others) Segment and Regional Forecasts, 2024 – 2032
Global Diabetes Devices Market Size, Share & Trends Analysis Report By Type (Blood Glucose Monitoring Devices, Insulin Delivery Devices, Continuous Glucose Monitoring Devices, Self-Monitoring Blood Glucose (SMBG) Systems), By Technique (Invasive, Non-Invasive), By Type (Wearable, Non-Wearable), By Distribution Channel, By End-use (Hospitals, Homecare, Institutional Sales, Retail Sales, Others) Segment and Regional Forecasts, 2024 – 2032
Size and Trends of the US Diabetes Devices Market
The market for diabetes devices in the United States is expected to continue with a steadfast compound annual growth rate (CAGR) of 6.14% till the year 2030, starting from a valuational point of USD 9.35 billion in 2025. The surge in this region is due to several factors such as the ever-increasing number of elderly persons and the growing incidence of lifestyle-induced cases of diabetes, increasing obesity, and high costs of treatment. The market is also driven by smart diabetes devices incorporated with advanced technologies such as AI or other data analytics capabilities.
A majority of individuals access healthcare services because of favorable reimbursement provision thus creating a demand for diabetes devices that are economical and efficient. Moreover, this created a need for inexpensive diabetes devices as well as integration with digital health into the care delivery system. Several organizations are thus seeking FDA approval before launching their products on the American market. A case in point is Insulet Corporation, which announced on January 6, 2022, that the U.S. FDA had approved Omnipod 5 Automated Insulin Delivery System for Americans with type 1 diabetes aged 6 years and above. The lifestyle system integrates with the Dexcom G6 Continuous Glucose Monitoring (CGM) System and smartphone automatically delivers insulin so as to prevent highs and lows. SDA health is enabled due to a more favorable reimbursement environment; hence, it creates a call for cheap and effective diabetes devices. This increases the demand for affordable diabetes devices and digital health inclusion into the care delivery process. Therefore, many companies are requesting FDA approval before putting their products into the American market. For instance, Insulet Corporation announced on January 6, 2022, the US FDA approval of Omnipod 5 Automated Insulin Delivery System for Americans aged 6 years and older living with type 1 diabetes. The user simply integrates the system with the Dexcom G6 Continuous Glucose Monitoring (CGM) System and smartphone: automatically delivers insulin and thus prevents highs and lows. Most people’s healthcare now, thanks to favorable reimbursement. This creates an affordable need for diabetes devices that affect both cost and efficacy. Rising demands for affordable diabetes devices and integration of digital health into the system of care delivery also increased the demand. So many businesses are thus seeking FDA approval before putting their products into the American market. For example, Insulet Corporation announced on January 6, 2022, that the U.S. FDA had approved the Omnipod 5 Automated Insulin Delivery System on the use of people aged 6 and up with type 1 diabetes in America. The user simply integrates the system with the Dexcom G6 Continuous Glucose Monitoring (CGM) System and smartphone: automatically delivers insulin and thus prevents highs and lows.
As stated by the Centers for Disease Control and Prevention (CDC), 34.2 million Americans-including both diagnosed and undiagnosed cases-suffer from diabetes. The affected population makes up 10.5% of the total population. Membership has been added, too, to a growing number of people with high blood glucose levels who fall just short of being classified as diabetic, or remain undiagnosed. Unhealthy diets, physical inactivity, and heredity are just a few reasons contributing to the rise in obesity and diabetes. Heart disease, stroke, and some cancers are major health problems that these can potentially increase the risk for. Growing initiatives by governments and nonprofit organizations to foster awareness about diabetes will help gather momentum for the adoption of diabetes devices. For example, the WHO Diabetes Program aims to prevent type 2 diabetes, reduce its complications, and improve quality of life for those with diabetes. Several NGOs and governments are drawing norms and standards, creating awareness on diabetic prevention, and building surveillance to strengthen prevention & control of diabetes. Hence, amplification of the awareness programs will boost the diagnosis of diabetes, which will obviously propel the adoption of diabetic devices.
Market Concentration & Characteristics
The total U.S. diabetes devices market is growing very actively as there are a number of new developments, mergers and acquisitions, partnerships, collaborations, and so on. Even though there are several regulations regarding the market, it is still expected to be favorable. Furthermore several product and regional expansion strategies are also being adopted by the key market players. The degree of innovation in the U.S. diabetes devices market is quite high. Having undergone rapid changes resulting primarily from technological innovation and new product launches, the healthcare sector in America is experiencing transformation on a large scale. The trend of digitizing healthcare around optimum innovative technology such as AI, big data, and cloud computing is being adopted by this country. Such market entrants are introducing different products to build their portfolios. Hence, by this strategy, the companies manage to reach more customers than increase their product portfolio and better their offerings. For example, in July 2021, Ascensia Diabetes Care, a new patient assistance program was launched by the company in the U.S. against the out-of-pocket costs of the Eversense CGM System.
The tremendous market activity in mergers and acquisitions (M&A) is followed by a slew of headline-grabbing transactions in which many leading market players acquire smaller players to make their market positions stronger. Thus, companies increase their capabilities and diversify their product lines in a single step. Consequently, the major players in the market are adapting several strategies like mergers & acquisitions, partnerships & collaborations, etc. in order to be competitive in the market space. Insulet Corporation, in February 2023, paid a huge amount for acquiring patents from Bigfoot Biomedical (Bigfoot), an organization associated with insulin delivery technologies.
Promising government policies associated with increasing funding for R&D are also expected to churn out innovative demand products. There are strict regulations for marketing devices like insulin pumps and pens, which will delay new devices in the market. Governments are proposing regulation-related devices on test strips and diabetic needles, which form major parts of insulin pens. Through this regulation, the costs of these products will be kept at an affordable range for the rural patient pool.
The driving factors beyond all these will be obesity and more costs for treatments, coupled with technology advancement and new product launches and expansions over time. Leading manufacturers are opening their markets and shares by focusing on establishing advanced products in the rural sector. The advanced and innovative product launches are expected to support the market growth. For instance, Cardiff University and GlucoRx Limited launched the first non-invasive continuous glucose monitor for needle-free blood glucose monitoring in patients clinically suffering from diabetes in September 2022.
For a continuing need to counter the burden of diabetes, developed countries are getting on board and, more than ever, investing in diabetes prevention, screening, and management. This entails opportunities for organizations to partner their government agencies and health care providers in developing and implementing diabetes care solutions. Further, they have also set their sights on launching diversified products and other initiatives to lead populations in various regions. An example is Ascensia Diabetes Care’s launching of GlucoContro-online, an analytics and online diabetes management platform, in the U.S. in November 2022, which is thus available in over 15 countries.
Market Segmentation
The blood glucose meter market segments according to products include continuous glucose monitoring devices and self-monitoring blood glucose systems. Based on techniques, the market is classified into invasive and non-invasive. By type, the global markets are categorized into wearable and non-wearable. The wearable type is expected to register a comparatively higher CAGR during the forecast period.On the basis of the distribution channel, the market segments include institutional sales and retail sales.In this regard, the gradual shift bodes well for the online pharmacies segment with regard to growth at a comparatively higher CAGR during 2019-2026. This is likely to fuel the blood glucose meter market demands.
Type Insights
In 2023, the insulin delivery devices market gained the highest revenue share at 54.19%. This segment includes pens, pumps, syringes, and jet injections. Again, while insulin pumps have risk factors such as causing diabetic ketoacidosis if the catheter kinks or clogs, the pen category, on the other hand, brings benefits such as portability, and it’s kid-friendly. This means that insulin syringes are anticipated to be replaced by convenience alternatives like pumps and pens. Jet injectors can be painful and cause skin bruises if not used properly, and they are more expensive than the other devices, as well as time-consuming for preparing the insulin dose. Thus, adoption of these devices is minimal and is likely to remain so during the forecast period.
The BGM devices market, on the other hand, is expected to grow at a relatively faster CAGR over the forecast period. There are low-cost blood glucose monitors that are reading glucose levels with greater accuracy in the body. Besides, with the technological advancements along with the launches of innovative and integrated solutions, most companies are coming up with low-cost, high-tech, user-friendly devices that would increase the value of the blood glucose monitoring devices market.
Distribution Channel Analysis
The hospital pharmacies segment captured the largest revenue share of 54.13% in 2023. Continuous glucose monitoring is expected to be necessary among diabetic patients in intensive care, post-cardiothoracic surgery, and receiving insulin therapy after discharge from the hospital, which is expected to increase the demand for CGM devices. In addition, the FDA has recently announced the approval for hospitals to allow patients to self-test their blood glucose levels through self-monitoring blood glucose meters because of the prevalence of COVID-19. The above factors have caused a massive hike in the inventory levels of self-monitoring glucose meters, resulting in tremendous growth for the segment.
The fastest-growing region in terms of CAGR during the forecast period is expected to be retail pharmacies because they are seen as the most easily accessed purchasing point for patients. Retail pharmacies certainly are one of the bigger chunks of the total diabetes device distribution volume. Such self-monitoring glucose supplies insulin delivery equipment, and OTC products offered by retail pharmacies are dependent on physician preference, patient preference, profit margin, and insurance coverage, among others.
Regional Analysis
“North America Dominates Blood Glucose Meter Research Because of Increasing Diabetic Population and Rise in the Adoption of Non- Invasive Blood Glucose Meters.”
North America generated maximum revenue worth US$ 3,012.6 Million in the year 2018 and is ranked second behind Europe then is expected to take lead in the global market for the remaining forecasted period. New demand and adoption of cutting-edge wearable & continuous blood glucose meters in the U.S., as well as increasing patient pool suffering from diabetes contribute to the growing share of North America in the global market in 2018.
Asia Pacific is set to register the highest CAGR in the period between 2019 and 2026, owing to the increasing penetration of glucose monitoring, rising patient awareness, and increasing per capita healthcare spending in that region. The share of the Middle East & Africa and Latin America markets was considerably smaller in 2018.
End-use Insight
In 2023, the highest share of revenue generated was from the hospital segment at 40.80%. Due to increased incidences of diabetes mellitus, the majority of hospitals and health care settings have turned to using continuous glucose monitor (CGM) devices for blood sugar monitoring. NCBI notes that clinical studies involving gestational diabetes mellitus have shown CGM devices higher performance than self-monitoring blood glucose (SMBG) devices. With the innovation of new-generation devices for diabetes management, the adoption of blood glucose monitoring devices in hospitals is anticipated to grow.
In the forecast period, the diagnostics centers segment will be the fastest growing in terms of CAGR. They include these glucose monitoring devices in their facility as diabetic patients tend to visit diagnostic centers to check their glucose levels owing to the advantage that such centers provide immediate results rather than having to wait long. Hence, demand for BGM devices will be anticipated to enhance the growth of the segment.
Major Drivers of the Market
Dexcom Inc., a leading player in continuous blood glucose meters around the world, scores highly owing to a strong portfolio and distribution network for continuous blood glucose meters across the globe. In order to bolster their position in the overall market, the leading key players are looking to launch more wearable and non-invasive blood glucose meters on a global basis. Dexcom Inc. along with F. Hoffmann-La Roche Ltd. Abbott and Medtronic had a leading share in the global market in 2018. Other players operating in the blood glucose meter market include Lifespan Inc., Ascensia Diabetes Care Holdings AG., Terumo Medical Corporation, Sanofi, DiaMonTech GmbH and others.
U.S. Diabetes Devices Companies:
- Medtronic plc
- Abbott Laboratories
- F.Hoffmann-La-Ltd.
- Bayer AG
- Lifescan, Inc.
- B Braun Melsungen AG
- Lifescan, Inc.
- Dexcom Inc.
- Insulet Corporation
- Ypsomed Holdings
- Companion Medical
- Sanofi
- Valeritas Holding Inc.
- Novo Nordisk
Recent Developments
In February 2023, Insulet Corporation acquired the assets of a California-based company, Automated Glucose Control LLC (AGC), which specializes in its automated insulin delivery technology. Ypsomed Holding AG established the new autoinjector platform called YpsoMate 5.5 in November 2022, which cost a mouthwatering 1.5-5.5 ml of liquid medication. Ascensia Diabetes Care launched GlucoContro. online in November 2022, a US-based analytics service and an online platform for diabetes management.
Facilities of a Report
High investment by market players into non-invasive and wearable continuous blood glucose monitoring devices, coupled with the increasing patient awareness towards self-monitoring in emerging economies, and developments made by market players on new software and mobile apps that allow the sharing of data and logging of data from the continuous blood glucose meters have been identified as some of the factors expected to have a direct bearing on the sales revenue of blood glucose meters. The report reveals qualitative and quantitative insights into industry trends on blood glucose meters and provides a deep dive into the segmentation in terms of market size and growth for all potential segments into which the market might be divided. The market is segmented byproduct, technique, type, distribution channel, and geographical remit.
On the product basis, the global market spend stands divided into continuous glucose monitoring and self-monitoring blood glucose systems. On the method basis, the market can be segmented into invasive and non-invasive. On the basis of type, it can be divided into wearables and non-wearables. The blood glucose device market is segmented into institutional sales and retail sales, based on distribution channel. The segment of institutional sales is further divided into hospitals, clinics, and others. The retail sales category is divided into hospital pharmacies, retail pharmacies, and online pharmacies. In terms of geography, the market is segmented into five major regions-north America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The countries further categorize these regions.
Along with that, blood glucose meter market reports include industry dynamics and competitive landscape in the blood glucose meter industry. Much signature insights that are included in the report encompass diabetes prevalence and incidence by key countries, recent industry developments i.e., mergers & acquisitions, pricing analysis, technological advancements, and strong industry trends.
By Income Segmentation Reports for the U.S. Diabetes Devices Market
Revenue forecasts for each of the countries along with analysis of key trends in the industry are included for the sub-segments from 2018 to 2030. In view of this study based on Grand View Research, the report on U.S. diabetes devices market is segmented into type, distribution channel, and end-use categories.
- Type Outlook (Revenue, USD Million, 2018 – 2030)
-
- BGM Devices
-
-
- Self-Monitoring Devices
-
-
-
- Blood Glucose Meters
-
-
-
- Testing Strips
-
-
-
- Lancets
-
-
- Continuous Glucose Monitoring Devices
-
-
- Sensors
-
-
-
- Transmitters
-
-
-
- Receiver
-
-
- Insulin Delivery Devices
-
-
- Pumps
-
-
-
- Pens
-
-
-
- Syringes
-
-
-
- Jet Injectors
-
- Distribution Channel Outlook (Revenue, USD Million, 2018 – 2030)
-
- Hospital pharmacies
-
- Retail Pharmacies
-
- Diabetes Clinics/Centers
-
- Online Pharmacies
-
- Others
- End-use Outlook (Revenue, USD Million, 2018 – 2030)
-
- Hospitals
-
- Diagnostic Centers
-
- Homecare
Key Industry Announcements
In June 2018, BioTel CareTM, in the house of next-generation wireless blood glucose meters to be used for diabetes management, was cleared by the FDA as the first-ever cellular-enabled glucometer-specific narrow-window real-time patient data transmission and consolidation within an FDA-cleared cloud.
In June 2018, OK Biotech Co., Ltd. unveiled a new portable model of blood glucose meter. This is a compact closer-to-zero non-invasive glucose meter.
In August 2017, ARKRAY USA, Inc., announced that it is going to lunch the GLUCOCARD Shine XL blood glucose monitoring system. The GLUCOCARD Shine XL BGMS has a well-designed ergonomic meter for optimum grip during testing, and it presents the results via a large LED display.
Greatest Opportunities Available to Manufacturers of Blood Glucose Monitoring Devices
The true burgeoning demand with respect to blood glucose monitoring devices would be coming from the rallying of the diabetes population and with the continual advancement in technologies for detecting glucose level in the blood.
Type 2 diabetes was exclusive to adults, but now it is infiltrating the younger generation. As the number of affected children keeps climbing, blood glucose measurements become an important practice.
The number of women diagnosed with diabetes during pregnancy is increasing. More complication arises during both production and delivery among such women. These are just some of the factors that have opened the way for the blood glucose monitoring devices market.
Obstacles for Blood Glucose Monitoring Device Market
One of the major reasons that blood glucose monitoring systems are not used to their full potential, especially in emerging economies, is that a sizable number of the population suffers from undiagnosed diabetes itself. Common chronic disorders like diabetes mellitus are not known well to the general populace. Moreover, the absence of standard operating procedures by public or commercial organizations and a limited advanced healthcare infrastructure could hinder further expansion.
Country-wise Insights
China Blood Glucose Monitoring Device Market
The market will increase owing to product availability, increased awareness of consumers, and penetration of companies into the country.
Government initiatives and activities raising awareness about diabetes management will contribute to business growth. For instance, the “National Diabetes Programme” (WDF02-036) initiative in China, funded by the World Diabetes Foundation (WDF), targets people with diabetes using treatment and capacity building across the health system in the country.
Blood Glucose Monitoring Devices Market in the United States
Rising number of obesity cases is one of the significant causes of type 2 diabetes amongst the USA population. According to the Centers for Disease Control and Prevention, the obesity prevalence rate in the United States from 2017 to March 2020 stood at 41.7%.
According to CDC estimates for the year 2020, about 1.5 million new cases of diabetes were diagnosed in the USA This is a major driver for manufacturing blood glucose monitoring devices in the country.
The Blood Glucose Monitoring Devices Market in Germany
The strict regulation of the price and reimbursement policies is driving the market. For instance, Germany’s Federal Joint Committee has reimbursed Dexcom for its continuous glucose monitoring system among patients dependent on insulin both with type 1 and type 2 diabetes.
Some emerging possibilities for these companies in the diabetes care devices market include launching numerous new products and further international research collaborations for technological advancement.
Blood Glucose Monitoring Devices Market in the UK
The increase in awareness about blood glucose management to individuals is anticipated to fuel the market across the region. Furthermore, increasing awareness about the relationship between blood glucose levels and chronic diseases is also expected to result in significant opportunities for the market during the forecast period.
Category-Wise Insights
| Attributes | Details |
| By Product Type | Self-Monitoring Devices |
| Market Share in 2024 | 72.4% |
Self-monitoring devices are supposed to witness growth at a CAGR of 4.5% till the end of the projected period holding nearly about 71.4% of the share in the global market by 2022.
Self-monitoring has made it convenient to consider the repeated blood tests for the assessment of diabetes control and to signal for changes for better control.
Technologically assisted self-monitoring is regarded as safe and efficacious in delivering positive health effects.
| Attributes | Details |
| By Distribution Channel | Retail Pharmacy |
| Market Share in 2024 | 40.2% |
Retail pharmacies have maximum occupancy in the distribution channel segment with a market share of 38.2% in the year 2022 since retail pharmacies keep a wide range of options for blood glucose monitoring devices.
Retail pharmacies are also quite available, hence preferred by many when they want to purchase blood glucose monitoring devices.
Frequently Asked Questions About This Report
What is the size of the US market for diabetes devices?
The diabetes devices market in the US has been valued at USD 9.53 billion in the year 2023 and is anticipated to reach a value of USD 10.22 billion by the year 2024.
What is the growth of the U.S. diabetes devices market?
The U.S. diabetes devices market is projected to grow at a compound annual growth rate of 6.91% during the forecast period of 2024 to 2030 to reach USD 15.21 billion by 2030.
Which segment constituted the significant U.S. diabetes devices market share?
The U.S. diabetes devices market was mainly dominated by the hospital pharmacies segment over 50% in 2024, which had extremely high footfall and availability of products.
Who are the key players in the U.S. diabetes device market?
Some of the major players in the U.S. diabetes device market include Abbott Laboratories; F.Hoffmann-La-Ltd.; Bayer AG; Lifescan, Inc.; B Braun Melsungen AG; Lifescan, Inc.; Dexcom Inc.; Insulet Corporation; Ypsomed Holdings; Companion Medical; Sanofi; Valeritas Holding Inc.; Novo Nordisk; and Arkray, Inc.
What are the driving forces of the U.S. diabetes devices market?
Major segments of the market are well established healthcare sector, increasing prevalence of obesity, and high cost of treatment, along with technology advancement and products launch.
Through what sales forecast is the market for the Blood Glucose Monitoring Devices expected through 2033?
The aforementioned market is likely to be approximately USD 22.2 billion at the end of 2033 and probably a 4.6% CAGR in the revenue amount to expected sales.
What key trends shape the Blood Glucose Monitoring Devices industry today?
These key trends include: Increased diabetes incidence in tandem with obesity due to modification of lifestyle and eating habits alongside increasing incidences of diabetes associated with aging that makes the development of innovative non-invasive and speedy methods to monitor blood glucose levels an imperative action to be established and pursued.
What is the outlook for blood glucose monitoring device market in North America?
North America was among the best addresses of markets blood glucose monitoring devices in which the USA accounts for almost 92.5% revenues from Blood Glucose Monitoring Devices market in North America in the year 2022.
What percentage will growth be to feature in demand for Blood Glucose Monitoring Devices across Europe?
Demand for Blood Glucose Monitoring Devices is expected to scale a register of 4.2% growth over the next decade in Europe.
